Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yajuan Cui

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Journal of Advanced Research|July 15, 2025
Identification of Bruceine A as a novel HSP90AB1 inhibitor for suppressing hepatocellular carcinoma growthWeijun Peng, Dazun Shi, Die Xu, et al.
Journal of Cancer|September 20, 2021
Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapyYanjuan He, Duanfeng Jiang, Kaixuan Zhang, et al.
Haematologica|July 6, 2014
Calreticulin mutations in Chinese with primary myelofibrosisBing Li, Junqing Xu, Jingya Wang, et al.
Cancer Communications (London, England)|August 22, 2020
Targeting lactate dehydrogenase A (LDHA) exerts antileukemic effects on T-cell acute lymphoblastic leukemiaHaizhi Yu, Yafei Yin, Yifang Yi, et al.
Experimental Hematology & Oncology|April 30, 2016
A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromesGege Feng, Robert Peter Gale, Wen Cui, et al.
Stem Cell Investigation|October 26, 2016
<i>TET2</i> mutations were predictive of inferior prognosis in the presence of <i>ASXL1</i> mutations in patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
Experimental Hematology & Oncology|May 29, 2015
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
Cell Research|October 17, 2015
Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signalsXudong Wu, Ida Holst Bekker-Jensen, Jesper Christensen, et al.
Cancer Letters|March 20, 2022
Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myelomaHaiqin Wang, Xiaojuan Xiao, Zhenzhen Li, et al.
Nucleic Acids Research|March 17, 2023
The novel GATA1-interacting protein HES6 is an essential transcriptional cofactor for human erythropoiesisZi Wang, Pan Wang, Jieying Zhang, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Advanced Research|July 15, 2025
Identification of Bruceine A as a novel HSP90AB1 inhibitor for suppressing hepatocellular carcinoma growthWeijun Peng, Dazun Shi, Die Xu, et al.
Journal of Cancer|September 20, 2021
Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapyYanjuan He, Duanfeng Jiang, Kaixuan Zhang, et al.
Haematologica|July 6, 2014
Calreticulin mutations in Chinese with primary myelofibrosisBing Li, Junqing Xu, Jingya Wang, et al.
Cancer Communications (London, England)|August 22, 2020
Targeting lactate dehydrogenase A (LDHA) exerts antileukemic effects on T-cell acute lymphoblastic leukemiaHaizhi Yu, Yafei Yin, Yifang Yi, et al.
Experimental Hematology & Oncology|April 30, 2016
A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromesGege Feng, Robert Peter Gale, Wen Cui, et al.
Stem Cell Investigation|October 26, 2016
<i>TET2</i> mutations were predictive of inferior prognosis in the presence of <i>ASXL1</i> mutations in patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
Experimental Hematology & Oncology|May 29, 2015
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
Cell Research|October 17, 2015
Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signalsXudong Wu, Ida Holst Bekker-Jensen, Jesper Christensen, et al.
Cancer Letters|March 20, 2022
Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myelomaHaiqin Wang, Xiaojuan Xiao, Zhenzhen Li, et al.
Nucleic Acids Research|March 17, 2023
The novel GATA1-interacting protein HES6 is an essential transcriptional cofactor for human erythropoiesisZi Wang, Pan Wang, Jieying Zhang, et al.
Pageof 4